Abbott Laboratories (ABT)

Currency in USD
123.67
+3.16(+2.62%)
Closed·
After Hours
123.80+0.13(+0.11%)
·
ABT Scorecard
Full Analysis
Has raised its dividend for 11 consecutive years
Unusual trading volume
Fair Value
Day's Range
122.27125.63
52 wk Range
99.92141.23
Key Statistics
Prev. Close
120.51
Open
122.63
Day's Range
122.27-125.63
52 wk Range
99.92-141.23
Volume
19.57M
Average Vol. (3m)
6.64M
1-Year Change
21.21%
Book Value / Share
28.05
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABT Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
141.59
Upside
+14.49%
Members' Sentiments
Bearish
Bullish
ProTips
17 analysts have revised their earnings downwards for the upcoming period

Abbott Laboratories News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company provides pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.

Abbott Laboratories SWOT Analysis


Analyst Perspectives
Learn about Abbott's average price target of $143, with estimates ranging from $133 to $159, reflecting varied views on its growth potential and market dynamics.
Innovation Leadership
Delve into Abbott's product breakthroughs, including the PFA System's early European approval and exceptional growth in diabetes care, driving market position.
Financial Fortitude
Explore Abbott's robust financial metrics, including $42.3B revenue, 56% gross margin, and 31% ROE, with 2025 guidance projecting 7.5-8.5% top-line growth.
Diversified Dominance
Abbott's multi-segment portfolio drives resilience, with strong organic growth and a 3.2 Financial Health Score, positioning it well in the healthcare sector.
Read full SWOT analysis

Abbott Laboratories Earnings Call Summary for Q2/2025

  • Q2 2025 EPS of $1.26 beat $1.25 forecast; revenue of $11.42B exceeded $11.07B estimate, up 6.9% YoY
  • Stock fell 7.21% pre-market despite earnings beat, closing at $124.54; market cap remains strong at $212.26B
  • Core business growth offset declining COVID test sales; Libre CGM and new product launches drove performance
  • Company forecasts high single-digit sales growth for 2025, projects similar growth with double-digit EPS rise for 2026
  • CEO highlights resilient, diversified model; focus on innovation and biosimilars expansion to drive future growth
Last Updated: 07/17/2025, 10:20 AM
Read Full Transcript

Compare ABT to Peers and Sector

Metrics to compare
ABT
Peers
Sector
Relationship
P/E Ratio
15.4x−12.0x−0.5x
PEG Ratio
0.10−0.310.00
Price / Book
4.4x4.9x2.6x
Price / LTM Sales
5.0x3.7x3.2x
Upside (Analyst Target)
15.3%43.8%44.3%
Fair Value Upside
Unlock−22.9%6.6%Unlock

Analyst Ratings

20 Buy
8 Hold
1 Sell
Ratings:
29 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 141.59
(+14.49% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 8.01%
Dividend Yield
1.91%
Annualized Payout
2.36
Paid quarterly
5-Years Growth
+10.63%
Growth Streak

Earnings

Latest Release
Jul 17, 2025
EPS / Forecast
1.26 / 1.25
Revenue / Forecast
11.42B / 11.07B
EPS Revisions
Last 90 days

ABT Income Statement

People Also Watch

151.50
RTX
0.00%
189.26
ABBV
-1.12%
105.42
FTNT
+0.48%
75.95
NEE
+1.02%
163.70
JNJ
+0.44%

FAQ

What Is the Abbott Labs (ABT) Stock Price Today?

The Abbott Labs stock price today is 123.67

What Stock Exchange Does Abbott Labs Trade On?

Abbott Labs is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for Abbott Labs?

The stock symbol for Abbott Labs is "ABT."

Does Abbott Labs Pay Dividends? What’s The Current Dividend Yield?

The Abbott Labs dividend yield is 1.91%.

What Is the Abbott Labs Market Cap?

As of today, Abbott Labs market cap is 215.17B.

What Is Abbott Labs's Earnings Per Share (TTM)?

The Abbott Labs EPS (TTM) is 8.01.

When Is the Next Abbott Labs Earnings Date?

Abbott Labs will release its next earnings report on Oct 15, 2025.

From a Technical Analysis Perspective, Is ABT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Abbott Labs Stock Split?

Abbott Labs has split 7 times.

How Many Employees Does Abbott Labs Have?

Abbott Labs has 114000 employees.

What is the current trading status of Abbott Labs (ABT)?

As of Jul 20, 2025, Abbott Labs (ABT) is trading at a price of 123.67, with a previous close of 120.51. The stock has fluctuated within a day range of 122.27 to 125.63, while its 52-week range spans from 99.92 to 141.23.

What Is Abbott Labs (ABT) Price Target According to Analysts?

The average 12-month price target for Abbott Labs is USD141.58615, with a high estimate of USD159 and a low estimate of USD120.12. 20 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +14.49% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.